⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL10361835 | 0.98 | — | — | |
| SCHEMBL9316416 | 0.66 | MAPT (0.45) | — | |
| SCHEMBL28917256 | 0.66 | — | — | |
| SCHEMBL3293293 | 0.66 | MAPT (0.39) | — | |
| SCHEMBL3466683 | 0.62 | — | — | |
| SCHEMBL3294386 | 0.57 | TSHR (0.46) | — | |
| SCHEMBL3296075 | 0.57 | ALDH1A1 (0.36) | — | |
| SCHEMBL486333 | 0.56 | — | — | |
| SCHEMBL27318360 | 0.55 | — | — | |
| SCHEMBL3293694 | 0.55 | ALDH1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12213976-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240228448-A1 | COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1), IMAGING OF S1P1, AND PROCESSES FOR PREPARATION THEREOF | WASHINGTON UNIVERSITY (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230110495-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11504367-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| WO-2022212769-A1 | COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1), IMAGING OF S1P1, AND PROCESSES FOR PREPARATION THEREOF | WASHINGTON UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-114980886-A | Compounds and methods for treating oxalate-related diseases | 奥沙鲁克斯公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-4017490-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | Oxalurx, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021035196-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20210052586-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-1451162-A1 | SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6759538-B2 | PREVENTION INFECTIONS OF HEPATITIS C VIRUS | RIGEL PHARMACEUTICALS, INC. | 2004-07-06 | — | — | US | disclosed |
| US-20030165561-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | MIDCAP FINANCIAL TRUST | 2003-09-04 | — | — | US | disclosed |
| WO-2003040112-A1 | SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-0747357-B1 | Dihydropyridine NPY antagonists: piperidine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2002-01-09 | — | — | EP | disclosed |
| US-5635503-A | TREATMENT OF EATING DISORDERS, PROMOTING WEIGHT LOSS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0747356-A1 | Dihydropyridine NPY antagonists: piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0747357-A2 | Dihydropyridine NPY antagonists: piperidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0747378-A1 | Dihydropyridine NPY antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5554621-A | Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-09-10 | — | — | US | disclosed |